FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like Boston Scientific Loses $3B on Latest Lotus Valve Delay November 28, 2017 Why Intercept Pharma Stock Jumped Nearly 10% On Friday After Providing Phase III Update February 9, 2017 Voyager Founder and CEO to Step Down, Hunt for New Leader Begins January 31, 2018
Why Intercept Pharma Stock Jumped Nearly 10% On Friday After Providing Phase III Update February 9, 2017
